Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, EP Winer, H Mukai, K Tamura, A Armstrong, MC Liu, H Iwata, L Ryvo, P Wimberger, HS Rugo, AR Tan, L Jia, Y Ding, V Karantza, P Schmid
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019
BACKGROUND: Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are needed. In cohort B of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as first-line therapy for patients with PD-L1-positive mTNBC. PATIENTS AND METHODS: Eligible patients had centrally confirmed mTNBC, no prior systemic anticancer therapy for metastatic disease, measurable disease at baseline per RECIST v1.1 by central review, no radiographic evidence of central nervous system metastases, and a tumor PD-L1 combined positive score ≥1. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 y..View full abstract
This work was supported by Merck Sharp & Dohme Corp. (no grant number applies), a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. There are no grants associated with this manuscript.